In its latest quarterly update, Aclarion reported ongoing operating losses with modest revenue growth as commercialization of its NOCISCAN diagnostic platform continues at a measured pace. The company’s business model leverages exclusive biomarker patents combined with spectroscopic data analysis to non-invasively identify painful spinal discs, aiming to improve surgical decision-making in chronic discogenic pain. Strategic collaborations and efforts to broaden MRI scanner compatibility and payer reimbursement codes underpin the growth strategy, although adoption remains limited by entrenched diagnostic incumbents and reimbursement uncertainty. Aclarion’s healthy cash position provides a runway to fund these initiatives, but realizing scalable commercial success will depend on overcoming reimbursement, scanner dependency, and market penetration hurdles.